# The Warburg Effect Redefined: A Kinetic and Regulatory Perspective

**Authors:** Amal Bhanu Vayakkattil, Aiswarya S Pazhanchery, Shibu Andrews, Udayabhanu Vayakkattil

PMC · DOI: 10.7759/cureus.93331 · 2025-09-27

## TL;DR

The Warburg effect is a regulated metabolic strategy in cancer cells that promotes tumor growth through increased glycolysis and lactate production.

## Contribution

The paper redefines the Warburg effect as a kinetic and regulatory adaptation, not a hypoxia-induced dysfunction.

## Key findings

- Lactate dehydrogenase's higher catalytic capacity drives pyruvate to lactate when pyruvate dehydrogenase is saturated.
- Membrane remodeling and transporter upregulation enhance glycolytic flux and lactate efflux in cancer cells.
- Metabolite-induced epigenetic changes stabilize the Warburg effect and support tumor proliferation.

## Abstract

The Warburg effect, characterized by the preferential conversion of glucose to lactate despite adequate oxygen availability, constitutes a regulated metabolic adaptation rather than a mere dysfunctional response to hypoxia. This metabolic shift arises because lactate dehydrogenase (LDH) exhibits a significantly higher catalytic capacity compared to pyruvate dehydrogenase (PDH), resulting in a substantial reduction of pyruvate to lactate once PDH becomes saturated. In cancer cells, this kinetic preference is further amplified by the upregulation of glucose and monocarboxylate transporters (GLUT1, MCT1, and MCT4) and alterations to the plasma membrane, which enhance transport efficiency. These adaptations maintain a high glycolytic flux, facilitate continuous lactate efflux, and circumvent traditional feedback inhibition. The accumulation of glycolytic intermediates supports the biosynthesis of nucleotides, lipids, and proteins, thereby promoting tumorigenesis. Over time, metabolite-induced DNA methylation and chromatin remodeling reinforce this metabolic state, stabilizing the oxygen-independent proliferative phenotype. Consequently, the Warburg effect is best conceptualized as a primary metabolic strategy initiated by membrane remodeling, sustained by kinetic flux imbalances, and perpetuated by epigenetic feedback, collectively enabling tumor growth and survival in adverse microenvironments.

## Linked entities

- **Proteins:** SLC2A1 (solute carrier family 2 member 1), CMA1 (chymase 1), SLC16A4 (solute carrier family 16 member 4)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, PDP1 (pyruvate dehydrogenase phosphatase catalytic subunit 1) [NCBI Gene 54704] {aka PDH, PDP, PDPC, PDPC 1, PPM2A, PPM2C}, SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123] {aka MCT 3, MCT 4, MCT-3, MCT-4, MCT3, MCT4}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}
- **Diseases:** tumorigenesis (MESH:D063646), cancer (MESH:D009369), hypoxia (MESH:D000860)
- **Chemicals:** lactate (MESH:D019344), glucose (MESH:D005947), oxygen (MESH:D010100), pyruvate (MESH:D019289), lipids (MESH:D008055)

---
Source: https://tomesphere.com/paper/PMC12557456